Entero Accounts Payable vs Non Current Assets Total Analysis
| ENTO Stock | 0.47 0.01 2.17% |
Entero Therapeutics, financial indicator trend analysis is much more than just examining Entero Therapeutics, latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Entero Therapeutics, is a good investment. Please check the relationship between Entero Therapeutics, Accounts Payable and its Non Current Assets Total accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.
Accounts Payable vs Non Current Assets Total
Accounts Payable vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Entero Therapeutics, Accounts Payable account and Non Current Assets Total. At this time, the significance of the direction appears to have weak relationship.
The correlation between Entero Therapeutics,'s Accounts Payable and Non Current Assets Total is 0.33. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Entero Therapeutics,, assuming nothing else is changed. The correlation between historical values of Entero Therapeutics,'s Accounts Payable and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Entero Therapeutics, are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Accounts Payable i.e., Entero Therapeutics,'s Accounts Payable and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.33 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Accounts Payable
An accounting item on the balance sheet that represents Entero Therapeutics, obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Entero Therapeutics, are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Entero Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Entero Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.At this time, Entero Therapeutics,'s Selling General Administrative is very stable compared to the past year. As of the 29th of November 2024, Issuance Of Capital Stock is likely to grow to about 18.6 M, though Enterprise Value is likely to grow to (1.5 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 542.3K | 29.3K | 29.3K | 27.8K | Interest Income | 1.2K | 8.4K | 2.5K | 3.5K |
Entero Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Entero Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving together with Entero Stock
Moving against Entero Stock
| 0.64 | ELAN | Elanco Animal Health | PairCorr |
| 0.62 | HLN | Haleon plc | PairCorr |
| 0.6 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.51 | ZTS | Zoetis Inc | PairCorr |
| 0.42 | TAK | Takeda Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.